ProKidney (PROK): EV/EBITDA Multiple

Public company logo of ProKidney Inc. (PROK)

Investment risks for ProKidney Corp. (PROK) are linked to clinical trial uncertainty and a reliance on external funding. However, the brand maintains high authority in the field of kidney regeneration. The company is currently finalizing trials for a therapy designed to delay dialysis. The EV/EBITDA ratio on the GURU.Markets valuation chart visualizes the business valuation trend, where the current status is 0.00.

ProKidney Inc. - PROK Enterprise Value to Operating Income Before Depreciation (period 11/23/2025 - 11/11/2026)

PROK (prokidney.com): analytical breakdowns and indicator data

- market price and analyst price targets:
Price Chart ProKidney Inc.|PROK - Analyst Consensus Forecast
- stock exchange capitalization data:
Market Capitalization ProKidney Pharma|PROK - Company Buyout Price
- issuer book value statistics:
Book Value per Share ProKidney|PROK - Accounting Capitalization|Market Value to Book Value Ratio prokidney.com|PROK - Total Business Assets
- company liabilities and liquidity data:
Total Debt to Capital ProKidney Corp.|PROK - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio ProKidney|PROK - Company Cumulative Debt|Debt to Book Capitalization Ratio ProKidney Pharma|PROK - Long-Term Liabilities|Company Short-Term Debt ProKidney|Quick Liquidity prokidney.com
- financial results and valuation multiples details:
PROK - Company Net Income|Expected Profit ProKidney Corp.|PROK - P/E Multiple|Forward P/E Multiple ProKidney Corp.|PROK - Growth-Adjusted Market Cap to Net Income|EV/EBITDA Multiple ProKidney Pharma|PROK - Operating profit before amortization|Earnings per share for the last twelve months ProKidney|PROK - Earnings per share for the last 12 months|Quarterly EPS earnings growth prokidney.com|PROK - Earnings per share growth rate in current year|Expected earnings per share growth for next year ProKidney Corp.
Initial company analysis:PROK (ProKidney Inc.)
Product sample of ProKidney Corp

This indicator compares the total enterprise value, including net debt, with its operating profit before depreciation and amortization, determining the asset's real price relative to its generated cash flow. The current EV/EBITDA ratio of ProKidney Corp. (PROK), accounting for a debt load of 0.00, is critically important, as it reveals the overvaluation of clinical failure risks amid venture cell therapy developments and the fierce competition for capital.

Direct competitors

Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Retrophin TVTX|EV/EBITDA Multiple Ardelyx Corp ARDX|Akebia Therapeutics - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio caratherapeutics.com TVRD|DMAC: EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation UNCY|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Rockwell Medical, Inc.|Enterprise Value to Operating Income Before Depreciation CVKD (Cadrenal Therapeutics Inc)|EV/EBITDA Multiple CDT|CALT - Company Value to EBITDA|Renalytix PLC - Enterprise Value to EBITDA Ratio|ZyVersa Therapeutics Inc. (ZVSA) - Company Value to EBITDA